On June 6, ImmunityBio fell 5.01% in regular trading, trading at approximately $6.90/share, with trading volume of $53.76 million. The stock has been under sustained selling pressure since late May, extending a pattern of profit-taking following a cluster of positive catalysts.

On the news front, ImmunityBio had previously released a dense series of catalysts, including positive AUA clinical efficacy data, an ISPOR health economics analysis demonstrating that ANKTIVA combined with BCG is more cost-effective than TAR-200, and a competitive landscape boost from rival enGene's key clinical data failure. Despite a brief 5.66% rebound on May 26 driven by AUA data, the stock subsequently declined 5.12% on May 29, indicating that profit-taking pressure from the realized catalysts has not been fully absorbed.

ImmunityBio is a clinical-stage immunotherapy company focused on activating innate and adaptive immune systems to treat cancers and infectious diseases, with platforms spanning natural killer cell therapy, antibody cytokine fusion proteins, and vaccine vectors.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)